However, recent findings suggest that beta-CGRP could play an important role in the pathophysiology of gastrointestinal symptoms, as exemplified by their specific increase in COVID-19 patients with diarrhea [10], or by its reduction in early phases of inflammatory bowel disease (IBD) [11]. This evidence concerns the gene CALCB and irritable bowel syndrome.